AstraZeneca, Argenx Score Phase III Wins in Autoimmune Space

Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.

Related Keywords

Seanj Pittock ,Argenx Vyvgart ,Astrazeneca Ultomiris ,Catherine Broome ,Mayo Neuroimmunology Laboratory ,Drug Administration ,Mayo Clinic Center ,Mayo Clinic ,Multiple Sclerosis ,Autoimmune Neurology ,Soliris Prevent ,Biologic License Application ,Primary Immune ,Associate Professor ,Georgetown University ,Lombardi Comprehensive Cancer Center ,Resume ,Careers ,Astrazeneca ,Rgenx Score Phase Iii Wins In Autoimmune Space ,Iospace ,Advice ,